SYDNEY (Azat TV) – Apple has activated its hypertension notification feature for Apple Watch users in Australia, a significant expansion of its health-focused offerings now available in seven additional countries. Launched on January 28, 2026, this advanced alert system leverages the smartwatch’s optical heart sensor to detect potential signs of chronic high blood pressure, a condition often dubbed a ‘silent killer’ due to its lack of obvious symptoms and its status as a leading cause of heart attacks and strokes.
This rollout is particularly crucial given the global prevalence of hypertension. The World Health Organization (WHO) reported in 2024 that an estimated 1.4 billion adults aged 30–79 worldwide had hypertension, with approximately 600 million unaware of their condition. Apple estimates that its new feature could notify over 1 million individuals with previously undiagnosed hypertension within its first year of availability, marking a pivotal moment in leveraging wearable technology for public health.
The New Health Feature in Action
The hypertension notification system, introduced with watchOS 26, operates by passively analyzing data from the Apple Watch’s optical heart sensor over 30-day periods. It scrutinizes how users’ blood vessels respond to heartbeats, employing sophisticated machine learning algorithms trained on data from over 100,000 participants and clinically validated in a study involving more than 2,000 individuals. This rigorous development process underscores Apple’s commitment to scientific validation for its health features.
Crucially, the Apple Watch does not provide an actual blood pressure reading. Instead, if the watch detects consistent signs correlated with potential hypertension, it alerts the user. Upon receiving an alert, users are advised to measure their blood pressure using a third-party cuff over a week, ideally scheduling readings in the morning and evening. All recorded data can be logged in the iPhone Health app and compiled into a PDF report, which can then be shared with a healthcare professional for assessment and diagnosis.
The feature is compatible with Apple Watch Series 9 and later, including Apple Watch Ultra 2 and subsequent models, all running watchOS 26. However, Apple explicitly states that the alerts are not intended for individuals under 22 years old, those already diagnosed with hypertension, or pregnant users. The feature is also not available on the more budget-friendly Apple Watch SE models.
Regulatory Path and Medical Perspective
The activation of hypertension notifications in Australia followed a necessary regulatory clearance. The software powering the feature was added to the Australian Register of Therapeutic Goods (ARTG) on December 4, 2025. The Therapeutic Goods Administration (TGA) classified it as “self-care monitoring web-based application software” and placed it in Class IIa, signifying a mid-risk medical device within Australia’s classification system. This regulatory approval was a prerequisite for its public release in the country.
Medical professionals in Australia have largely welcomed the feature, albeit with cautious optimism. Dr. Ramya Raman, Vice President of the Royal Australian College of General Practitioners (RACGP), described the Apple Watch alert as ‘a starting point,’ emphasizing its role as a helpful prompt for users to seek further medical evaluation. Similarly, GP Dr. David Adam noted that an Apple Watch alert ‘should prompt appropriate confirmation’ from a healthcare professional, underscoring that the device is not a diagnostic tool.
Professor Garry Jennings, chief medical advisor at the Australian Heart Foundation, praised the technology, highlighting the alarmingly low awareness of hypertension in Australia. He stated that new tools advising people they might have hypertension, thereby prompting them to seek medical confirmation, are invaluable. However, doctors also cautioned that the feature might inadvertently ‘increase aspects of health anxiety’ for some users or, conversely, provide a false sense of security.
Global Expansion and Key Caveats
Beyond Australia, Apple simultaneously expanded the hypertension notification feature to six other countries: Brazil, Colombia, Indonesia, Malaysia, South Korea, and Turkey. This broad rollout brings the total number of supported countries and regions to 170, significantly advancing Apple’s global health initiative. The feature’s availability is rolled out through a server-side update, ensuring broad access for eligible users.
Despite its advanced capabilities, Apple is transparent about the feature’s limitations. The company’s support documentation explicitly states that the Apple Watch ‘is not a medical device,’ cannot detect heart attacks, and will not catch every instance of hypertension. Users are strongly advised that the alerts are not a substitute for professional medical advice, diagnosis, or treatment. This critical distinction aims to manage user expectations and ensure the feature serves as an awareness tool rather than a standalone medical solution.
While Apple expands its health suite, other tech giants are also venturing into this space. Samsung’s Galaxy Watch already offers a blood pressure app, though it requires calibration with a TGA-approved cuff monitor. Meanwhile, Google is conducting a study involving up to 10,000 participants to explore hypertension screening capabilities on its Pixel Watch devices, signaling a broader industry trend towards integrating advanced health monitoring into wearables.
The strategic expansion of Apple Watch’s hypertension notifications into key markets like Australia underscores a growing trend where consumer technology is increasingly positioned as a first line of defense in public health, shifting the paradigm from reactive treatment to proactive awareness and early intervention for widespread conditions.